A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy. In clinical trials, the treatment zorevunersen cut seizures by as much as 91% while also improving quality of life for many patients. The therapy works by boosting the function of a key gene involved in nerve cell signaling. Encouraging results have led researchers to launch a larger Phase 3 trial.
View the full article